Detalles de la búsqueda
1.
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Br J Cancer
; 130(3): 434-441, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38102226
2.
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Br J Cancer
; 128(1): 21-29, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36289372
3.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int
; 130(5): 592-603, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34597472
4.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(7): 931-945, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051178
5.
SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Prostate
; 81(16): 1267-1277, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34533858
6.
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
BJU Int
; 128(2): 196-205, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33556233
7.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31753727
8.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Cancer
; 126(6): 1208-1216, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829450
9.
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
J Urol
; 204(1): 63-70, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31971495
10.
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
BJU Int
; 126(5): 559-567, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32654362
11.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Int J Cancer
; 145(7): 1970-1981, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30807643
12.
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Prostate
; 79(10): 1156-1165, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31090082
13.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916371
14.
The Cancer Genome Atlas Project in Bladder Cancer.
Cancer Treat Res
; 175: 259-271, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30168126
15.
Is there an antiandrogen withdrawal syndrome with enzalutamide?
BJU Int
; 115(3): 373-80, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24906049
16.
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal.
Acta Derm Venereol
; 100(6): adv00079, 2020 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32115665
17.
VAV3 mediates resistance to breast cancer endocrine therapy.
Breast Cancer Res
; 16(3): R53, 2014 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24886537
18.
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
J Clin Pharmacol
; 64(5): 544-554, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105505
19.
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Clin Transl Oncol
; 26(6): 1532-1538, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38102374
20.
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFß) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Clin Transl Sci
; 17(2): e13736, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38362837